Join to View Full Profile
221 Longwood AveBoston, MA 02115
Dr. Anand is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Anand is Professor of Psychiatry at Harvard Medical School and Director of Translational Clinical Trials at Mass General Brigham. Dr. Anand completed his training from the All India Institute of Medical Sciences, the RANZCP and Yale University. He has conducted the first studies of use of ketamine and glutamatergic modulation and resting state brain connectivity in mood disorders.
Education & Training
Griffin HospitalResidency, Internal Medicine, 1994 - 1994
Yale-New Haven HospitalFellowship, Clinical Neuroscience, 1992 - 1994- Royal Australian and New Zealand College of PsychiatristsFRANZCP, Psychiatry, 1986 - 1991
All India Institute of Medical SciencesClass of 1985
Certifications & Licensure
MA State Medical License 2021 - 2026
OH State Medical License 2012 - 2025
IN State Medical License 2001 - 2017
CT State Medical License 1993 - 2007
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI Start of enrollment: 2011 Nov 01
- Genomics Used to Improve DEpression Decisions Start of enrollment: 2014 Apr 01
- Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression Start of enrollment: 2016 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D tri...Gerard Sanacora, Brian S Barnett, Bo Hu, Fernando S Goes, Sanjay J Mathew
Psychiatry Research. 2025-05-01 - 3 citationsKetamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial.Manish Kumar Jha, Samuel T Wilkinson, Kamini Krishnan, Katherine A Collins, Gerard Sanacora
JAMA Network Open. 2024-06-03 - 12 citationsFocal adhesion is associated with lithium response in bipolar disorder: evidence from a network-based multi-omics analysis.Vipavee Niemsiri, Sara Brin Rosenthal, Caroline M Nievergelt, Adam X Maihofer, Maria C Marchetto
Molecular Psychiatry. 2024-01-01
Authored Content
- The High Price of Ignoring Disease in the MarginalizedJuly 2020
- The High Price of Ignoring Disease in the MarginalizedJuly 2020
Press Mentions
Ketamine Shows Promise for Hard-to-Treat Depression in New StudyMay 26th, 2023- Ketamine Beats Shock Therapy in Easing Tough-to-Treat DepressionMay 25th, 2023
- Ketamine as Effective as Electroconvulsive Therapy for Treatment-Resistant DepressionMay 25th, 2023
- Join now to see all
Grant Support
- Ketamine Treatment of Youth Suicide Attempters for Fast Reduction of Severe Suicide Risk and Facilitation of Long-term Collaborative Clinical Engagement: A Randomized Placebo Controlled TrialCLEVELAND CLINIC LERNER COM-CWRU2020–2026
- Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar DisorderBRIGHAM AND WOMEN'S HOSPITAL2017–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
